Apr 28, 2022 7:05am EDT IMV’s Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting
Apr 08, 2022 5:00pm EDT IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting
Mar 17, 2022 7:05am EDT IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results
Mar 10, 2022 7:05am EST IMV Inc. to Announce Fourth Quarter and Fiscal Year 2021 Results and Host a Conference Call and Webcast on March 17, 2022
Mar 09, 2022 7:05am EST IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022
Jan 12, 2022 7:05am EST IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL